TICKERNERD
Menu
FTHHealthcare · Biotechnology

FTH Stock Forecast: Faeth Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$20
−7.02% on the day

The 14 Wall Street analysts covering Faeth Therapeutics, Inc. hold a median 12-month price target of $56 — +180.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 14 Oct 2026 — in the upper half.

Market cap
$555.8M
Ticker Nerd rank
57 / 100
Median analyst target
$56
Analysts covering
14
Revenue$0.0
Operating income−$18.4M
Net income−$16.0M
Free cash flow−$15.7M
Quarterly, 5 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−19.7%
1M
−48.8%
YTD
+87.4%
1Y
+57.0%
From 52W high
−50.1%
From 52W low
+153.5%
$8
$40
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FTH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Faeth Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
57 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
89
Momentum
71
Value
66
Revisions
62
Size
52
Volatility
51
Quality
42
Issuance
35
Growth
19

Accruals (89): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (19): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

FTH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FTH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Jan 26Apr 26Jul 26Oct 26FTHHigh $70Median $56Low $46

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
14 Buy0 Hold0 Sell
Low $46Median $56High $70

The green dot is the last close — the median target sits +180.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
16 Sept 2026GuggenheimInitiatesBuy$70
14 Sept 2026LUCID CAPITAL MARKETSInitiatesBuy$59
9 Sept 2026TD CowenInitiatesBuy—
21 Aug 2026NeedhamInitiatesBuy—
21 Aug 2026NeedhamInitiatesBuy$56
11 Aug 2026HC Wainwright & Co.ReiteratesBuy$60
11 Aug 2026HC Wainwright & Co.ReiteratesBuy—
4 Aug 2026Jones TradingInitiatesBuy$55
4 Aug 2026Jones TradingInitiatesBuy—
31 July 2026Raymond JamesInitiatesOutperform$56
31 July 2026Raymond JamesInitiatesOutperform—
28 July 2026OppenheimerInitiatesOutperform$60
28 July 2026OppenheimerInitiatesOutperform—
20 July 2026CitizensInitiatesMarket Outperform$51
20 July 2026CitizensInitiatesMarket Outperform—
16 July 2026BTIGReiteratesBuy—
16 July 2026BTIGReiteratesBuy$55
26 June 2026BairdInitiatesOutperform$57
26 June 2026BairdInitiatesOutperform—
22 June 2026HC Wainwright & Co.InitiatesBuy$60

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FTH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

FTH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Faeth Therapeutics, Inc. returned +57.0% against +17.5% for the S&P 500, dividends included.

FTH vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250300Jan 26Apr 26Jul 26Oct 26FTHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FTH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Faeth Therapeutics, Inc. (FTH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.3×

Cheaper than 84% of US stocks

Price / sales
—
Price / book
3.2×

Cheaper than 29% of US stocks

EV / EBITDA
−10.1×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−195.3%

Higher than 8% of US stocks

Return on assets
−20.8%

Higher than 19% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Faeth Therapeutics, Inc. (FTH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Faeth Therapeutics, Inc. has a market value of $555.8M and an enterprise value of $370.0M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$195.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$33.9M.

  • Faeth Therapeutics, Inc. spent $16.9M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 25.8M.

  • Trailing P/E: −1.3×; forward P/E: −4.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Faeth Therapeutics, Inc. employs 29 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

FTH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FTHFaeth Therapeutics, Inc.$555.8M
57
PBYIPuma Biotechnology, Inc.$519.1M
92
SGMTSagimet Biosciences, Inc.$530.7M
39
ACRSAclaris Therapeutics, Inc.$497.5M
66
STTKShattuck Labs, Inc.$534.9M
71
DRUGBright Minds Biosciences, Inc.$493.5M
43
MNPRMonopar Therapeutics, Inc.$488.5M
53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Faeth Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FTH news & analysis

Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug Expansion

Seeking Alpha · 18 Sept 2026positive

Seeking Alpha initiated coverage of Faeth Therapeutics (formerly a company that underwent acquisition and name change) with a "Buy" rating, following a $200M private placement. Its lead asset, PIKTOR, targets multi-node PAM pathway alterations in endometrial cancer and HR+/HER2- breast cancer, with phase 2 topline data for 2nd-line advanced endometrial cancer expected by year-end 2026 and interim breast cancer data in 2027.

Why it matters — FTH watchers would care because PIKTOR's upcoming topline catalysts in endometrial and breast cancer and the company's new positioning after its acquisition and $200M financing define the key near-term milestones for the firm.

Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors

Business Wire · 17 Sept 2026positive

Faeth Therapeutics announced the appointment of Karen Vousden, Ph.D., to its Board of Directors, effective September 11, 2026. The company noted that Vousden helped shape the scientific thesis on which Faeth was built and has served as a trusted advisor since its founding.

Why it matters — A FTH watcher would care because adding a scientist closely tied to the company's foundational research to the board may signal continued strategic alignment with its core scientific direction.

Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026

Business Wire · 8 Sept 2026neutral

Faeth Therapeutics announced it will host a virtual key opinion leader event on October 6, 2026 at 10:00 AM ET, featuring Marcus Goncalves, MD, PhD of NYU Langone Health and a scientific co-founder of Faeth, who will join company management to discuss the PAM (PI3K/AKT/mTOR) pathway in human cancer. The event will focus on multi-nodal inhibition for the treatment of endometrial cancer.

Why it matters — This upcoming KOL event may provide FTH watchers with additional clinical and scientific context on Faeth's PAM pathway approach and its lead program PIKTOR in endometrial cancer.

What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now?

Zacks Investment Research · 1 Sept 2026positive

Zacks Investment Research published an article examining whether Faeth Therapeutics, Inc. (FTH) qualifies as a strong momentum stock pick for investors. The piece evaluates the company's characteristics from the perspective of momentum investing.

Why it matters — The article signals that FTH is being evaluated as a potential strong momentum stock, drawing attention to the company's performance from an investment-research perspective.

Faeth Therapeutics to Participate in Upcoming September Investor Conferences

Business Wire · 1 Sept 2026neutral

Faeth Therapeutics announced that management will participate in upcoming investor conferences in September 2026, including the Wells Fargo 21st Annual Healthcare Conference and the Citibank Biopharma Back to School Summit, featuring a fireside chat and 1x1 investor meetings.

Why it matters — An FTH watcher would care because the company's participation in these investor conferences provides opportunities for management to update the investment community on its clinical-stage oncology programs, including its lead program PIKTOR.

FAQ

Frequently asked questions about FTH stock

What is the FTH stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Faeth Therapeutics, Inc. have a median 12-month price target of $56, with estimates ranging from $46 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FTH stock a buy right now?

Of the 14 analysts covering Faeth Therapeutics, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Faeth Therapeutics, Inc. 57 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FTH?

As at 14 Oct 2026, Faeth Therapeutics, Inc. ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (89 of 100).

Will FTH stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +180.0% from the last close, and Ticker Nerd's factor model ranks Faeth Therapeutics, Inc. 57 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FTH stock forecast for 2030?

No analyst covering Faeth Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FTH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $46 to $70 over the next 12 months.

How has FTH stock performed over the past year?

Faeth Therapeutics, Inc. returned +57.0% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Faeth Therapeutics, Inc. do?

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cancer therapies that combine metabolic and pathway-targeted approaches.

What is the latest news on FTH?

The most recent item we track (Seeking Alpha, 18 Sept 2026): "Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug Expansion". Seeking Alpha initiated coverage of Faeth Therapeutics (formerly a company that underwent acquisition and name change) with a "Buy" rating, following a $200M private placement. Its lead asset, PIKTOR, targets multi-node PAM pathway alterations in endometrial cancer and HR+/HER2- breast cancer, with phase 2 topline data for 2nd-line advanced endometrial cancer expected by year-end 2026 and interim breast cancer data in 2027.

Company

About Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cancer therapies that combine metabolic and pathway-targeted approaches. Its current work centers on PIKTOR, an investigational all-oral program built around multi-node inhibition of the PI3K/AKT/mTOR pathway for endometrial and breast cancer. The company’s platform is designed to pair therapeutic molecules with precision nutrition and related treatment strategies, reflecting its emphasis on cancer metabolism and tumor-specific vulnerabilities. Faeth Therapeutics also advances research aimed at improving outcomes for patients with solid tumors through clinically tested combinations and supportive digital tools. In today’s oncology market, the company occupies a specialized role at the intersection of biotechnology, metabolic intervention, and precision medicine.

CEO Mr. Anand Parikh Esq., J.D. · 29 employees · United States · https://www.faeththerapeutics.com